8 December 2025 - Merck announced today that the province of Saskatchewan has added Capvaxive, a 21 valent pneumococcal conjugate vaccine, to its publicly funded adult immunisation program. 

This addition supports increased access to pneumococcal immunisation for eligible adults in accordance with the provincial eligibility criteria.

Read Merck press release